Market Newsdesk

FUZHOU, China, Jan. 19, 2022 (GLOBE NEWSWIRE) — E-Home Household Service Holdings Limited (Nasdaq: EJH) (the “Company” or “E-Home”), a provider of integrated household services in China, today announced that the Company has set up a cleaning robot equipment leasing department in the cleaning service sector, highlighting to promote the growth of the Company’s cleaning service business.

The specific measures reveal in the cleaning robot equipment leasing department include:

• Import the high-tech cleaning robot equipment from Japan and the United States
• Improve market share and reduce labor cost of cleaning service business by the robot equipment
• Achieve multiple simultaneous use of the robot equipment by leasing the robot equipment to small and medium-sized enterprises
• Achieve an integration effect between robot equipment and cleaning service industry
• Use capital investment to improve the profitability of the robot equipment leasing business
• By robot equipment leasing business, E-Home access the cutting-edge technology of cleaning robot equipment, to improve its technological innovation ability
• Combine real lecturers and virtual lecturers by the metaverse technology, to provide the online training for the cleaning staff from time to time
• Establish a cleaning robot equipment technology docking group to ensure that traditional cleaning industry can improve profitability through technological innovation

Mr. Wenshan Xie, Chairman and CEO of E-Home, commented: “At present, with the improvement of office and home environment requirements, cleaning business is increasing year by year. However, the profits of most traditional cleaning companies are dragged down by cleaning equipment, labor costs, and outdoor personnel risks. Based on this, the Company decided at the recent 2022 business strategy meeting to set up a cleaning robot equipment leasing department. The new business segment will greatly reduce the operating cost of the cleaning department of the Company and improve the profit margin. In addition, with the support of high-tech robot equipment, it will also bring customers a brand new consumption experience, encourage and guide them to spread good corporate reputation information, so as to obtain a continuous competitive advantage in the industry. The new business is expected to contribute approximately $15 million in revenue and approximately $3 million in net income to the Company in 2022.”

Mr. Xie continued: “In this special period, this new project shows our determination to actively develop new businesses segment, and our innovation ability to flexibly respond to the market competition pressures. We believe that our strong technological innovation capabilities and diversified service strategies will drive our business to significant growth. At the same time, we look forward to offering customers more solutions in the future and further expanding our marketing channels.”

About E-Home Household Service Holdings Limited

E-Home Household Service Holdings Limited is a household service company based in Fuzhou, China. The Company, through its website and WeChat platform “e家快服”, provides integrated household services, including appliance installation and maintenance, housekeeping services, and Internet based home and senior care. For more information, visit the Company’s website at http://www.ej111.com/ir.html. 

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions are intended to identify such forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to consider risk factors, including those described in the Company’s filings with the SEC, that may affect the Company’s future results.
All forward-looking statements attributable to the Company and its subsidiaries or persons acting on their behalf are expressly qualified in their entirety by these risk factors.

Contact Person : Dong Cao

Cell Number: +86 13502048965

Email: [email protected]

SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in critical communications systems and solutions that help protect and keep people safe, today announced a $1.97 million public safety mass notification and emergency warning systems contract from the City of Berkeley, CA. Last year, Alameda County, CA, in which Berkeley is located, entered into a multi-year software services and evacuation management contract with Genasys’ Zonehaven.

“Berkeley and other communities are enhancing safety for residents and visitors by implementing fully integrated software and hardware emergency alerting and evacuation solutions,” said Richard Danforth, Chief Executive Officer, Genasys Inc. “The award from the city includes installing a network of our outdoor Integrated Mass Notification Systems (IMNS) that broadcast audible voice notifications with exceptional clarity and area coverage.

“In addition to satellite connectivity, solar power and battery backup, the IMNS installations will be activated and controlled as a network, or individually, with Genasys Emergency Management (GEM) software,” added Mr. Danforth. “Annual recurring software and system maintenance fees are also included in the multi-year contract.”

“The Genasys network will deliver city-wide or hyperlocal fire, flooding, tsunami, earthquake, and other public safety threat alerts to our 125,000+ citizens,” said Keith May, Assistant Fire Chief and Public Information Officer, Berkeley Fire Department. “IPAWS compatibility, remote activation and control, and the ability to continue operating in the event power or telecommunications infrastructure goes down are among the advantages of the Genasys system. Genasys speaker arrays and the Zonehaven evacuation management platform are important additions to the City’s emergency services resources.”

Genasys provides the only critical communications platform that unifies software, geo-data analytics, multiple sensor inputs, and multichannel alerting that includes industry leading voice speaker arrays.

About Genasys Inc.

Genasys^® is a global provider of critical communications systems and solutions that help protect and keep people safe. Genasys provides a multichannel approach to deliver geo-targeted alerts, notifications, instructions and information before, during and after public safety threats and critical business events. The Company’s unified critical communications platform includes Genasys Emergency Management (GEM) software-as-a-service, Integrated Mass Notification Systems (IMNS), Zonehaven™ emergency evacuation resources, National Emergency Warning Systems (NEWS), LRAD^® long-range voice broadcast systems, and more.

Genasys systems are in service in more than 100 countries in a range of diverse applications, including public safety, emergency warning, mass notification, critical event management, defense, law enforcement, homeland security, and other applications. For more information, visit genasys.com.

Forward-Looking Statements

Except for historical information contained herein, the matters discussed are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on these statements. We base these statements on particular assumptions that we have made in light of our industry experience, the stage of product and market development as well as our perception of historical trends, current market conditions, current economic data, expected future developments and other factors that we believe are appropriate under the circumstances. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, including without limitation the business impact of health crises or outbreaks of disease, such as epidemics or pandemics and how they may affect our supply chain, and other risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. Risks and uncertainties are identified and discussed in our filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management’s expectations as of the date hereof. Future results may differ materially from our current expectations. For more information regarding other potential risks and uncertainties, see the “Risk Factors” section of the Company’s Form 10-K for the fiscal year ended September 30, 2021. Genasys Inc. disclaims any intent or obligation to update those forward-looking statements, except as otherwise specifically stated.

Investor Relations Contact

Kimberly Rogers
Hayden IR

[email protected]

Company to Review Recently Announced $5 Billion of Offtake Contracts for SAF and RD

CUPERTINO, CA , Jan. 19, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on negative carbon intensity products, announced that Chairman and CEO Eric McAfee will provide an overview of the Aemetis Dairy RNG, Aviation Fuel, Renewable Diesel, Ethanol and Carbon Sequestration businesses at the 27th Annual Credit Suisse Energy Summit which will be held at the Grand Hyatt Vail in Vail, Colorado on February 28, 2022.   

McAfee will present on the topic “$5 billion of New Contracts for Aemetis Carbon Zero Renewable Fuels: Sustainable Aviation Fuel, Renewable Diesel, Dairy RNG, Ethanol, Biodiesel, CO2 Sequestration.” 

The Aemetis Carbon Zero, 90 million gallons per year, renewable jet/diesel fuel plant is currently completing engineering and permitting for the 125-acre Riverbank, California site.

“Aemetis has recently announced $2 billion of sustainable aviation fuel contracts with Delta Air Lines and American Airlines, with seven signed MOU’s for additional contracts with members of the oneworld Alliance,” stated McAfee. “In addition, we signed a $3.1 billion supply contract with a large travel stop company to provide renewable diesel to California locations.”

McAfee noted, “These final, signed contracts provide 100% of the LCFS, RFS, Blender’s Tax Credit and fuel value to Aemetis as the producer of the renewable fuel, and the aviation fuel is being supplied at a price premium over petroleum jet fuel.”  

Aemetis is also constructing a 52-site Dairy Renewable Natural Gas project near Modesto, California. Phase 1 of the RNG project with two dairy digesters and a 4 mile pipeline is completed and operational. Phase 2 of the project is under construction, including a biogas upgrading facility to produce RNG, a PG&E utility gas pipeline interconnect, 15 additional dairy digesters, and 32 miles of pipeline.

The Aemetis Biogas Central Dairy Digester project has already obtained a negative 426 (-426) carbon intensity rating from the California Air Resources Board (CARB) for biogas produced by Phase I.  

When fully built out, the planned 52 dairy digesters in the Aemetis biogas project are expected to capture more than 1.4 million MMBtu of dairy methane and reduce greenhouse gas emissions equivalent to an estimated 5.2 million metric tonnes of CO2 each year, equal to removing the emissions from approximately 1.1 million cars per year.  

The Aemetis Biogas dairy RNG project, energy efficiency upgrades to the Aemetis Keyes biofuels plant, and the Aemetis Renewable Jet/Diesel project include $57 million of grant funding and other support from the US Department of Agriculture, the US Forest Service, the California Energy Commission, the California Department of Food and Agriculture, CAEATFA, and Pacific Gas and Electric’s energy efficiency program.

About Aemetis

Aemetis has a mission to transform renewable energy with below zero carbon intensity transportation fuels. Aemetis has launched the Carbon Zero production process to decarbonize the transportation sector using today’s infrastructure. 

Aemetis Carbon Zero products include zero carbon fuels that can “drop in” to be used in airplane, truck, and ship fleets. Aemetis low-carbon fuels have substantially reduced carbon intensity compared to standard petroleum fossil-based fuels across their lifecycle. 

Headquartered in Cupertino, California, Aemetis is a renewable natural gas, renewable fuel and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace petroleum-based products and reduce greenhouse gas emissions.  Founded in 2006, Aemetis has completed Phase 1 and is expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis also owns and operates a 50 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe.  Aemetis is developing the Carbon Zero sustainable aviation fuel (SAF) and renewable diesel fuel biorefineries in California to utilize distillers corn oil and other renewable oils to produce low carbon intensity renewable jet and diesel fuel using cellulosic hydrogen from waste orchard and forest wood, while pre-extracting cellulosic sugars from the waste wood to be processed into high value cellulosic ethanol at the Keyes plant. Aemetis holds a portfolio of patents and exclusive technology licenses to produce renewable fuels and biochemicals.  For additional information about Aemetis, please visit www.aemetis.com.

Safe Harbor Statement 

This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to the development and construction of the carbon sequestration facilities, biogas lagoon digesters, biogas cleanup and compression unit, construction and operation of the biogas pipeline, our compliance with governmental programs, and our ability to access markets and funding to execute our business plan.  Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “showing signs,” “targets,” “view,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties.  Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2020 and in our subsequent filings with the SEC. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.

External Investor Relations

Contact:

Kirin Smith
PCG Advisory Group
(646) 863-6519
[email protected]

Company Investor Relations/

Media Contact:

Todd Waltz
(408) 213-0940
[email protected]

ATLANTA, Jan. 19, 2022 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, will release its financial results for the fiscal first quarter ended December 31, 2021 on January 31, 2022 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time on February 1, 2022 during which members of senior management will make a brief presentation focused on the financial results and operating trends. A question-and-answer session will follow. 

Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256. Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 8200479.

About DLH


DLH (NASDAQ:DLHC) delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit http://www.DLHcorp.com.

INVESTOR RELATIONS

Contact: Chris Witty
Phone: 646-438-9385
Email: [email protected]

 

Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents

Mean C

_max

of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of study compared to the lowest commercially available oral alternative

Findings from Phase 1b safety portion of study support trial continuation

Topline Phase 2a results expected in Q1 2022

BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has completed the Phase 1b portion of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD) (Study VY2021-01). FMX114 is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod. The product is being developed to address both the source and cause of inflammation in AD. FMX114 has the potential to be the first topical combination product for the treatment of AD as well as the first topical product in clinical development that utilizes the sphingosine 1-phosphate receptor modulation mode of action.

The objective of the Phase 1b portion of the study was to evaluate the preliminary clinical safety, dermal tolerance and pharmacokinetics of FMX114 and vehicle gels when topically applied for up to 2 weeks to individual qualifying atopic dermatitis lesions. The study planned to enroll up to 6 subjects with mild to moderate atopic dermatitis in this Phase 1b safety portion. However, based on the data obtained from the first two completing subjects, the Human Research Ethics Committee (HREC) in Australia overseeing the study agreed to reduce the enrollment number to 4 subjects with mild to moderate atopic dermatitis.

At the study baseline visit, each subject had two AD lesions of comparable severity and extent based on the Atopic Dermatitis Severity Index (ADSI) scoring assessment and qualifying lesions were randomized to either FMX114 or vehicle gel treatment. Adverse events, clinical laboratory results and local dermal tolerance data was collected throughout subject participation in the study. Pharmacokinetics of tofacitinib, fingolimod and fingolimod 1-phosphate were evaluated based on blood/plasma concentration data obtained from highly sensitive and validated bioanalytical methods.

Both FMX114 and vehicle gel treatments were generally well-tolerated, and no serious adverse events were recorded during study conduct. Pharmacokinetics of tofacitinib, fingolimod and fingolimod 1-phosphate are summarized below:

• The mean plasma C_max of tofacitinib calculated on treatment day 1 and day 14 were approximately 50-fold and 1500-fold lower, respectively, when compared to the equivalent data for the lowest commercially available adult oral dose of tofacitinib (XELJANZ 5mg BD).¹
  • The mean plasma C_max of tofacitinib was determined to be 0.914 ng/ml and 0.0220 ng/ml on treatment day 1 and 14 respectively (assay Lower Limit of Quantification [LLOQ]: 0.01ng/ml).
  • Systemic drug accumulation of tofacitinib was negligible over the dosing period, with an accumulation ratio calculation based on C_max of 0.03. In samples obtained one week after the end of treatment, tofacitinib was not quantifiable (<0.01ng/ml).
• The pharmacokinetics of fingolimod and active metabolite, fingolimod 1-phosphate could not be determined as all whole blood concentrations were below the assay LLOQ (0.08ng/ml for both analytes). The mean whole blood C_max for fingolimod and fingolimod 1-phosphate for the adult oral dose of fingolimod (GILENYA 0.5mg QD) is 3.7ng/ml and 1.8ng/ml respectively at steady state.²

Dr. Iain Stuart, Chief Scientific Officer of VYNE, stated, “FMX114 was designed to deliver both active drugs efficiently to the skin while minimizing their respective systemic exposures. We are encouraged by the results from the Phase 1b portion of study VY2021-01 and look forward to announcing top-line Phase 2a results later this quarter.”

About Study VY2021-01 (ClinicalTrials.gov Identifier: NCT04927572)

The Phase 1b/2a study is a randomized, double-blinded trial designed to compare the safety and efficacy of FMX114 gel with vehicle gel. The study is expected to enroll up to 31 subjects, with each subject serving as their own control. The enrollment criteria specifies that subjects must have two comparable target AD lesions for treatment upon entry. Participants will have FMX114 gel applied to one of these lesions and vehicle gel to the other. Up to six subjects will be initially treated twice daily with FMX114 and vehicle for up to two weeks to evaluate preliminary safety of FMX114 and the pharmacokinetics of tofacitinib, fingolimod and fingolimod 1-phosphate. A further 25 subjects will receive FMX114, and vehicle treatment applied twice daily for four weeks in a double-blinded phase of the study to further evaluate safety, pharmacokinetics and efficacy. After completion of this phase, these subjects may continue into a two-week open-label treatment phase and will be able to apply the active drug to both lesions. The trial is being conducted in Australia in subjects with mild-to-moderate atopic dermatitis (clinicaltrials.gov link) in two segments:

1. XELJANZ/XELJANZ XR/XELJANZ Oral Solution US Prescription Information, December 2021
2. Clinical Pharmacokinetics of Fingolimod, Clin Pharmacokinet 2012;51(1):15-28]

About FMX114

FMX114 is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod. The product is being developed to address both the source and cause of inflammation in AD by developing a distinct combination of tofacitinib (a Janus kinase inhibitor) aimed at reducing inflammation by inhibiting cytokine release from inflammatory cells) and fingolimod (a Sphingosine 1-phosphate receptor modulator) which approaches the reduction of inflammation by inhibiting migration of inflammatory cells, and in addition may also directly support skin barrier recovery. FMX114 has the potential to be the first topical combination product for the treatment of AD as well as the first topical product in clinical development that utilizes the sphingosine 1-phosphate receptor modulation mode of action.

About Atopic Dermatitis

Atopic dermatitis (AD) is a chronic, severe form of eczema that is characterized by the appearance of dry, red, and itchy skin. AD most commonly affects the cheeks, arms, and legs. Flare ups often occur and symptoms can worsen leading to more-intense itching and worsening of disease. AD flares are triggered by stress, temperature changes, sweat, various skin irritants, and allergies. AD can have a wide-ranging impact on quality of life and there is a substantial monetary burden from direct and indirect costs to this patient population. While AD occurs most often in childhood, it can develop at any point in a person’s lifetime and affects approximately 30 million people in the U.S. alone. Approximately 22 million of those diagnosed are on treatment, with 19 million registering mild to moderate disease.  According to Symphony Health data, there were over 7 million prescriptions written in 2019 alone for the treatment of AD.

About VYNE Therapeutics Inc.

VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:

John Fraunces
LifeSci Advisors, LLC
917-355-2395
[email protected]

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
[email protected]

Cautionary Statement Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the development and commercialization of VYNE’s product candidate, FMX114, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the outcome and cost of preclinical and clinical trials for current and future product candidates; determination by the FDA that results from VYNE’s preclinical and clinical trials are not sufficient to support registration or marketing approval of product candidates; adverse events associated with the development and commercialization of FMX114 and VYNE’s other product candidates; the COVID-19 pandemic and its impact on our business operations and liquidity, including our ability to progress a preclinical or clinical trial; the size of the atopic dermatitis market; the potential patient base and commercial potential of FMX114 or any of VYNE’s other product candidates; risks of potential litigation by third-parties regarding infringement of third-party intellectual property; risks that VYNE’s intellectual property rights, such as patents, may fail to provide adequate protection, may be challenged and one or more claims may be revoked or interpreted narrowly or will not be infringed; risks that any of VYNE’s patents may be held to be narrowed, invalid or unenforceable or one or more of VYNE’s patent applications may not be granted and potential competitors may also seek to design around VYNE’s granted patents or patent applications; additional competition in the markets in which we compete; inability to raise additional capital on favorable terms or at all; VYNE’s ability to recruit and retain key employees; and VYNE’s ability to stay in compliance with applicable laws, rules and regulations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in VYNE’s subsequent filings with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.

NASHVILLE, Tenn., Jan. 19, 2022 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today announced the expansion of its award-winning whitening product line with its new Fast-Dissolving Whitening Strips.

The new convenient and easy to use Fast-Dissolving Whitening Strips are the ideal whitening treatment for those who want results fast, without the mess of traditional whitening strips. With a short wear time – just once a day for 15 minutes – the Fast-Dissolving Whitening Strips are perfect for those who suffer from painful sensitivity caused by other longer-wear whitening strips. In just seven days, the new Strips can whiten teeth up to nine shades* in half the wear time when compared to 30-minute-wear strips.

SmileDirectClub is pleased to partner with Peloton star trainer Tunde Oyeneyin to help promote this exciting new launch and highlight the convenience of this innovative and highly effective whitening product. Like SmileDirectClub, Oyeneyin believes that a great smile has a transformational power to boost your self-confidence, making her an ideal partner for this launch. Throughout the partnership, Tunde will share how she incorporates the new Fast-Dissolving Whitening Strips into her self-care routine and how they have positively impacted her confidence.

“With the introduction of the Fast-Dissolving Whitening Strips, SmileDirectClub is revolutionizing the way we look at whitening teeth,” said Amy Keith, General Manager of Global Oral Care at SmileDirectClub. “The new Strips allow customers to customize their teeth whitening journey by applying them anywhere, anytime, making teeth whitening convenient and accessible no matter where or when you choose to whiten.”

The SmileDirectClub Fast-Dissolving Whitening Strips are available as a one-week ($30) or two-week ($45) treatment, available now on Shop.SmileDirectClub.com and Amazon and will be launching in over 4,600 Walmart locations in late February as well as other major retailers across North America later in Q1. The Fast-Dissolving Whitening Strips complement SmileDirectClub’s existing best-in-class product offerings, including a portfolio of top-selling whitening products as well as the recently released Water Flossers.

According to recent research, a majority of those surveyed believe having a whiter smile would boost their self-confidence. Additionally, almost half (40%) of individuals want to focus on their oral care – teeth whitening, cleaning, straightening – as a means of improving their overall health in 2022.**

SmileDirectClub is the only clear aligner brand that offers customers an end-to-end solution to keep teeth straighter, brighter and cleaner. Since its launch, SmileDirectClub has become one of the fastest-growing health technology companies and continues to be the leading telehealth platform for orthodontia.

About SmileDirectClub 
SmileDirectClub, Inc. (“SmileDirectClub”) is an oral care company and creator of the first medtech platform for teeth straightening. Through its cutting-edge telehealth technology and vertically integrated model, SmileDirectClub is revolutionizing the oral care industry. SmileDirectClub’s mission is to democratize access to a smile each and every person loves by making it affordable and convenient for everyone. SmileDirectClub is headquartered in Nashville, Tennessee and operates in the U.S., Canada, Australia, New Zealand, United Kingdom, Ireland, Hong Kong, Singapore, Spain, France and Mexico. For more information, please visit SmileDirectClub.com.

Contact: SmileDirectClub Media Relations: [email protected] 

* Maximum results when used as directed. Results may vary.  
** Source: Pollfish Survey, n=1,000 US Consumers, 16+ years old with representative market mix of gender, ethnicity, age group, HH income, and geographic location.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/589fe684-5e64-498e-9c86-670be3199eb3

https://www.globenewswire.com/NewsRoom/AttachmentNg/35e463be-86f0-4ed8-9da5-cc5fa3aadd1a

 

GUILFORD, Conn. and MINNEAPOLIS, Jan. 19, 2022 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine”), creator of the first U.S. Food and Drug Administration (“FDA”) cleared portable magnetic resonance imaging (“MRI”)™ device, Swoop®, is proud to announce that M Health Fairview is deploying a Swoop system in the emergency room (ER), intensive care unit (ICU) and post anesthesia environments at M Health Fairview University of Minnesota Medical Center. The hospital is the first in the state of Minnesota, and one of the first in the country, to offer this technology to its patients.

“Forward thinking academic institutions like University of Minnesota are leading the charge adopting new, robust technologies in support of advancing research and improving the care continuum,” said Dr. Khan Siddiqui, MD, Chief Medical Officer and Chief Strategy Officer, for Hyperfine. “Swoop was designed to address the complex issues these institutions face by eliminating long wait times and minimizing difficulties with transporting patients, all while improving staff workflow and reducing costs.”

Swoop’s portable design and easy-to-use interface make it accessible for use in hospitals, clinics, and other settings outside of the conventional MRI suite. Instead of requiring a team of three to four nurses to transport a critically ill patient to an MRI room on a different floor, the Swoop system can be wheeled straight to a patient’s bed. The Swoop system is also a fraction of the cost of a traditional MRI unit, which helps hospitals and patients save valuable time and financial resources.

Swoop® was designed to enable rapid diagnoses and treatment for every patient regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to life-saving care. In as little as 30 seconds after a Swoop scan, advanced artificial intelligence applications analyze and return annotated, segmented brain images, providing clinicians with quantitative markers for decision support and immediate feedback for diagnostic insight.

“Patient safety and advancing the standard of care for our patient are of the highest priority for M Health Fairview,” said Dr. Clark Chen, MD, PhD, M Health Fairview neurosurgeon, Lyle French Chair in Neurosurgery and the head of the University of Minnesota Medical School Department of Neurosurgery. “We have invested in a trial of the Hyperfine’s Swoop system because we believe that the technology enhances patient safety and represents the next stage of how artificial intelligence can redefine the future of patient care.”

Through deep learning and artificial intelligence-aided image reconstruction, Swoop is able to assess brain tissue in real-time which provides physicians the ability to make quick and informed clinical decisions for patients. Swoop results are displayed on a tablet and deliver crisp, clear T1, T2, FLAIR, and DWI (with ADC map) tissue contrasts within minutes before uploading the scans to local PACS (Picture Archive and Communications System).

The device also has a lower field strength than standard MRI systems which greatly enhances patient safety and shortens the time required for each MRI. These features allow clinicians to quickly scan, diagnose and treat patients within crowded healthcare environments like ERs, ORs, and ICUs. The device also eliminates the need for comprehensive metal detection, allowing for parents of pediatric patients to stay bedside while their children get life-saving scans.

To date, the Hyperfine Swoop Portable MRI System™ has been deployed at Yale New Haven Hospital, University of California Irvine Medical Center, Ohio State University Wexner Medical Center, and the University of Illinois at Chicago’s Surgical Innovation Training Lab.

For more information about the Hyperfine Swoop Portable MRI System, please visit http://www.hyperfine.io.

About Hyperfine and the Swoop Portable MR Imaging System

Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the world’s first FDA-cleared portable MRI system. Hyperfine designed Swoop to enable rapid diagnoses and treatment for every patient regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to life-saving care. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients in various clinical settings. Swoop can be wheeled directly to the patient’s bedside, plugged into a standard electrical wall outlet, and controlled by a tablet. Designed as a complementary system to conventional MRIs at a fraction of the cost, Swoop captures images in minutes, providing critical decision-making capabilities in emergency departments (ED), operating rooms (OR) outside the sterile field, and intensive care units (ICU), among others.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations about the benefits of Hyperfine’s products and services, their impact on the future of patient care, and M Health Fairview’s use of the Swoop system. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of Hyperfine’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of Hyperfine product development and commercialization activities, including the degree that Swoop is accepted and used by healthcare professionals; the impact of COVID-19 on Hyperfine’s business; the inability to maintain the listing of Hyperfine’s Class A common stock on the Nasdaq following the recently completed business combination; the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and Hyperfine’s ability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of Hyperfine to raise financing in the future; the inability of Hyperfine to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of Hyperfine to identify, in-license or acquire additional technology; the inability of Hyperfine to maintain its existing or future license, manufacturing, supply and distribution agreements; the inability of Hyperfine to compete with other companies currently marketing or engaged in the development of products and services that Hyperfine is currently marketing or developing; the size and growth potential of the markets for Hyperfine’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Hyperfine’s products and services and reimbursement for medical procedures conducted using Hyperfine’s products and services; Hyperfine’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; Hyperfine’s financial performance; and other risks and uncertainties indicated from time to time in Hyperfine’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. Hyperfine cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. Hyperfine does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contacts


Emily Barnes
APCO Worldwide
[email protected] 

Aimee Jordan
M Health Fairview
[email protected] 

GREENSBORO, N.C., Jan. 19, 2022 (GLOBE NEWSWIRE) — Qorvo^® (Nasdaq: QRVO), a leading provider of innovative RF solutions that connect the world, will host a conference call to review fiscal 2022 third quarter financial results on Wednesday, February 2, 2022, at 5:00 p.m. (ET). The conference call will be webcast live on the Company’s website at the following URL: http://www.qorvo.com (under “Investors”).

A telephone playback of the conference call will be available approximately two hours after the call’s completion and can be accessed by dialing 719-457-0820 and using the passcode 5371000. The playback will be available through the close of business February 9, 2022.

Qorvo will distribute fiscal 2022 third quarter financial results at approximately 4:00 p.m. (ET) on Wednesday, February 2, 2022.

About Qorvo

Qorvo (Nasdaq: QRVO) makes a better world possible by providing innovative Radio Frequency (RF) solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers’ most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including advanced wireless devices, wired and wireless networks and defense radar and communications. We also leverage unique competitive strengths to advance 5G networks, cloud computing, the Internet of Things, and other emerging applications that expand the global framework interconnecting people, places and things. Visit www.qorvo.com to learn how Qorvo connects the world.

Qorvo is a registered trademark of Qorvo, Inc. in the U.S. and in other countries. All other trademarks are the property of their respective owners.

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions, and are not historical facts and typically are identified by use of terms such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements included herein represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those expressed or implied by forward-looking statements. We do not intend to update any of these forward-looking statements or publicly announce the results of any revisions to these forward-looking statements, other than as is required under U.S. federal securities laws. Our business is subject to numerous risks and uncertainties, including those relating to fluctuations in our operating results; our substantial dependence on developing new products and achieving design wins; our dependence on several large customers for a substantial portion of our revenue; the COVID-19 pandemic materially and adversely affecting our financial condition and results of operations; a loss of revenue if defense and aerospace contracts are canceled or delayed; our dependence on third parties; risks related to sales through distributors; risks associated with the operation of our manufacturing facilities; business disruptions; poor manufacturing yields; increased inventory risks and costs due to timing of customer forecasts; our inability to effectively manage or maintain evolving relationships with platform providers; our ability to continue to innovate in a very competitive industry; underutilization of manufacturing facilities as a result of industry overcapacity; unfavorable changes in interest rates, pricing of certain precious metals, utility rates and foreign currency exchange rates; our acquisitions and other strategic investments failing to achieve financial or strategic objectives; our ability to attract, retain and motivate key employees; warranty claims, product recalls and product liability; changes in our effective tax rate; changes in the favorable tax status of certain of our subsidiaries; enactment of international or domestic tax legislation, or changes in regulatory guidance; risks associated with environmental, health and safety regulations and climate change; risks from international sales and operations; economic regulation in China; changes in government trade policies, including imposition of tariffs and export restrictions; we may not be able to generate sufficient cash to service all of our debt; restrictions imposed by the agreements governing our debt; our reliance on our intellectual property portfolio; claims of infringement of third-party intellectual property rights; security breaches and other similar disruptions compromising our information; theft, loss or misuse of personal data by or about our employees, customers or third parties; provisions in our governing documents and Delaware law may discourage takeovers and business combinations that our stockholders might consider to be in their best interests; and volatility in the price of our common stock. These and other risks and uncertainties, which are described in more detail in Qorvo’s most recent Annual Report on Form 10-K and in other reports and statements filed with the Securities and Exchange Commission, could cause actual results and developments to be materially different from those expressed or implied by any of these forward-looking statements.

At Qorvo^®
Doug DeLieto
VP, Investor Relations
1-336-678-7968

JERSEY CITY, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) — Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced it has been selected by Vodafone Turkey to transform and automate the operator’s testing activity in line with Vodafone’s group-wide Tech 2025 modernization journey.

The three-year deal for end-to-end quality engineering services will enable Vodafone Turkey to create a next-generation quality engineering organization by establishing a Testing Center of Excellence. This will embrace an Agile/DevTestOps ‘shift-left’ approach to testing – ensuring faster time to market, improved productivity and operational efficiency. As part of the agreement, Amdocs is providing an outcome-based quality engineering modernization roadmap and will implement Ginger, its signature open-source automation framework.

“We’re pleased to be working hand in hand with Amdocs on this important project to modernize and automate our testing processes in line with our vision,” said Cem Sever, head of quality organization at Vodafone Turkey. “Using open-source automation framework for continuous integration/continuous deployment (CI/CD) implementations, we look forward to delivering tangible operational and customer-experience benefits.”

“At Amdocs we’re on a mission to simplify the complex and deliver the amazing. That’s why we’re excited to be embarking on this significant, wide-ranging transformation project that will ensure Vodafone Turkey is future-ready and able to achieve its digital ambitions,” said Ronen Levkovich, president, Amdocs Global Services. “Our role in establishing the Testing Center of Excellence will involve a combination of Amdocs Quality Engineering resources with local talent – allowing for maximum flexibility to scale up as needed. Ultimately the transformation will deliver significant benefits for Vodafone Turkey’s customers by ensuring that new products and services can be developed, tested and brought to market quicker.”

Supporting Resources

• Keep up with Amdocs news by visiting the company’s website
• Follow us on Twitter, Facebook, LinkedIn and YouTube

About Amdocs

Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers’ innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and enterprise customers. Our 28,000 employees around the globe are here to accelerate service providers’ migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $4.3 billion in fiscal 2021. For more information, visit www.amdocs.com

Amdocs’ Forward-Looking Statement

This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ growth and business results in future quarters. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general economic conditions, Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company’s products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, the Company specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs’ filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2021 filed on December 10, 2021.

Media Contacts

Michael Youds
Amdocs Public Relations
Tel: +44 7855 827 038
Email: [email protected]

Holly Abbott
Babel PR for Amdocs
Tel: +44 (0)7527 521057
Email: [email protected] / [email protected]

SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) — Oportun (Nasdaq: OPRT), a mission-driven fintech company, and Sezzle (ASX: SZL), a leading mission-driven Buy Now Pay Later (BNPL) solution, today announced a partnership that will provide consumers more choice when financing higher value purchases at many of Sezzle’s 44,000 online merchant partners.

“This is a significant expansion of our Lending-as-a-Service platform, and we are excited to welcome Sezzle as our first digital-only partner,” said Matt Jenkins, COO of Oportun. “Importantly, both of our companies are mission-aligned and committed to providing consumers with responsible, affordable, and transparent financing options that will help them build a credit history.”

Through the partnership, consumers choosing to purchase higher value items including electronics and other home goods, will have the option at checkout to finance their purchase through Oportun. Using machine learning and billions of proprietary data points, Oportun is able to score 100% of its loan applicants. Historically, about half of Oportun borrowers had no credit score when they took out their first Oportun loan, and since 2006, the company has helped nearly 1 million American consumers to start building a credit score, while saving them more than $2 billion in interest and fees.

“We are excited to partner with Oportun as they will help us expand our mission by making additional responsible and affordable financing options available to consumers who rely on Sezzle to help them with their everyday and special occasion shopping needs,” said Rob Seidman, Vice President of Long-Term Product at Sezzle. “In seeking long-term financing options for our marketplace, mission alignment and ability to digitally scale with our needs were of paramount importance, and we look forward to a successful partnership with Oportun.”

Oportun noted that with the addition of Sezzle, their Lending-as-a-Service business now includes three strategic partners, with Sezzle being the first all-digital partner.

About Oportun

Oportun (Nasdaq: OPRT) is a digital banking platform that uses A.I. to make financial health effortless for anyone. Oportun helps its 1.4 million members meet their daily borrowing, banking, savings, and investing needs. Since its inception, Oportun has provided more than $10 billion in responsible and affordable loans; Oportun’s members have also set aside more than $7 billion for rainy days and other needs, saved more than $2 billion on interest and fees, and paid down more than $300 million in personal debt. In recognition of its responsibly designed products and its mission to provide inclusive and affordable financial services that empower hardworking individuals to build a better future, Oportun has been certified as a Community Development Financial Institution (CDFI) since 2009.

Media Contact
George Gonzalez
650-769-0441
[email protected]

Investor Contact
Nils Erdmann
650-810-9074
[email protected]